To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Stratagene Highlights Results of FDA's MicroArray Quality Control Project
Stratagene Corporation has highlighted the U.S. Food and Drug Administration's (FDA) publication of results from its MicroArray Quality Control (MAQC) project.
As part of the FDA's Critical Path Initiative, the MAQC project aimed to develop standards and quality measures for the microarray community, so that microarrays, as a core technology of pharmacogenomics and toxicogenomics, could be used in clinical practice and regulatory decision-making.
As a result, the MAQC project will help improve microarray technology and foster its proper applications in the discovery, development and review of FDA regulated products.
"We are proud to have been a part of this collaboration that brought together a broad range of academic, governmental, and commercial organizations, all with the future of microarray technology in mind," said Joseph A. Sorge, MD, President and CEO of Stratagene.
"Stratagene's Universal Reference RNA was one of two high-quality reference standards selected as part of the MAQC project."
"These reference RNAs allow laboratories with many different microarray platforms to compare and share data in the global microarray community."
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
